Arcus Biosciences (RCUS) has provided an update.
Arcus Biosciences unveiled promising interim results from its Phase 2 EDGE-Gastric trial, assessing the efficacy of combining domvanalimab, zimberelimab, and chemotherapy in treating upper gastrointestinal cancers. The data revealed a median Progression-Free Survival of 12.9 months overall, with higher rates in PD-L1-high patients. The Objective Response Rate stood at 58.5%, demonstrating the treatment’s potential. Additionally, the safety profile was consistent with expectations, with the most common side effects being infusion-related reactions. These encouraging findings indicate a significant step forward in gastrointestinal cancer therapy.
Learn more about RCUS stock on TipRanks’ Stock Analysis page.